Urticarial vasculitis - Vasculitis Urticarial
☆ Ann an toraidhean 2022 Stiftung Warentest às a’ Ghearmailt, cha robh sàsachd luchd-cleachdaidh le ModelDerm ach beagan nas ìsle na le co-chomhairlean telemedicine pàighte.
References
Is e suidheachadh tearc a th’ ann an Urticarial vasculitis air a chomharrachadh le tachartasan maireannach no ath-chuairteachaidh de shnàthadan. Ged a dh’ fhaodadh na comharran craiceann aige a bhith coltach ri corragan leantainneach, tha iad gun samhail leis gu bheil na sràcan a’ cumail timcheall airson co-dhiù 24 uair agus faodaidh iad spotan dorcha adhbhrachadh às deidh dhaibh crìonadh. Ged a tha e tric gun adhbhar neo-aithnichte, uaireannan faodaidh e a bhith air a phiobrachadh le cungaidhean sònraichte, galairean, galairean fèin-dìon, eas-òrdughan fala, no cansearan. Tha cuid de sgrùdaidhean eadhon air a cheangal ri cnatan mòr COVID-19 agus H1N1. Faodaidh e cuideachd buaidh a thoirt air pàirtean eile den bhodhaig leithid fèithean, dubhagan, sgamhanan, stamag, agus sùilean. Ged a dh'fhaodas seòrsa sònraichte de sgrùdadh clò a dhearbhadh air a 'bhreithneachadh, chan eil e an-còmhnaidh riatanach. Bidh làimhseachadh mar as trice a’ tòiseachadh le antibiotics, dapsone, colchicine, no hydroxychloroquine airson cùisean nas ciùine. Airson cùisean nas cruaidhe, dh’ fhaodadh gum bi feum air drogaichean a chuireas stad air an t-siostam dìon mar methotrexate no corticosteroids. O chionn ghoirid, tha leigheasan bith-eòlais (rituximab, omalizumab, interleukin-1 inhibitors) air gealltanas a nochdadh airson cùisean duilich.
Urticarial vasculitis is a rare clinicopathologic entity that is characterized by chronic or recurrent episodes of urticarial lesions. Skin findings of this disease can be difficult to distinguish visually from those of chronic idiopathic urticaria but are unique in that individual lesions persist for ≥24 hours and can leave behind dusky hyperpigmentation. This disease is most often idiopathic but has been linked to certain drugs, infections, autoimmune connective disease, myelodysplastic disorders, and malignancies. More recently, some authors have reported associations between urticarial vasculitis and COVID-19, as well as influenza A/H1N1 infection. Urticarial vasculitis can extend systemically as well, most often affecting the musculoskeletal, renal, pulmonary, gastrointestinal, and ocular systems. Features of leukocytoclastic vasculitis seen on histopathologic examination are diagnostic of this disease, but not always seen. In practice, antibiotics, dapsone, colchicine, and hydroxychloroquine are popular first-line therapies, especially for mild cutaneous disease. In more severe cases, immunosuppressives, including methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine, as well as corticosteroids, may be necessary for control. More recently, select biologic therapies, including rituximab, omalizumab, and interleukin-1 inhibitors have shown promise for the treatment of recalcitrant or refractory cases.
Urticarial vasculitis is a rare clinicopathologic entity that is characterized by chronic or recurrent episodes of urticarial lesions. Skin findings of this disease can be difficult to distinguish visually from those of chronic idiopathic urticaria but are unique in that individual lesions persist for ≥24 hours and can leave behind dusky hyperpigmentation. This disease is most often idiopathic but has been linked to certain drugs, infections, autoimmune connective disease, myelodysplastic disorders, and malignancies. More recently, some authors have reported associations between urticarial vasculitis and COVID-19, as well as influenza A/H1N1 infection. Urticarial vasculitis can extend systemically as well, most often affecting the musculoskeletal, renal, pulmonary, gastrointestinal, and ocular systems. Features of leukocytoclastic vasculitis seen on histopathologic examination are diagnostic of this disease, but not always seen. In practice, antibiotics, dapsone, colchicine, and hydroxychloroquine are popular first-line therapies, especially for mild cutaneous disease. In more severe cases, immunosuppressives, including methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine, as well as corticosteroids, may be necessary for control. More recently, select biologic therapies, including rituximab, omalizumab, and interleukin-1 inhibitors have shown promise for the treatment of recalcitrant or refractory cases.
Thàinig fireannach 35-bliadhna a-steach le eachdraidh 15-latha de bhroth dearg, goirt air gach sliasaid agus casan, còmhla ri pian co-phàirteach. Bha galar slighe urinary air airson seachdain mus do nochd am broth. Sheall a chraiceann grunn chlàran dearga tairgse, cumadh fàinne, gu ìre so-ruigsinneach air gach taobh de a shliasaid agus a chasan. Chaidh prednisolone beòil (40mg / day) a thoirt dha airson seachdain còmhla ri antihistamine neo-thruagh (fexofenadine) . Taobh a-staigh seachdain, chaidh na brògan gu lèir à sealladh. Cha robh barrachd bhroth ann anns na 6 mìosan a tha romhainn de sgrùdaidhean cunbhalach.
A 35-year-old man came in with a 15-day history of bright red, painful rashes on both thighs and legs, along with joint pain. He had a urinary tract infection for a week before the rash appeared. His skin showed several tender, ring-shaped, partially blanchable, red plaques on both sides of his thighs and legs. He was given oral prednisolone (40mg/day) for a week along with a non-drowsy antihistamine (fexofenadine). Within a week, all the rashes disappeared completely. There were no more rashes during the next 6 months of regular check-ups.
A 35-year-old man came in with a 15-day history of bright red, painful rashes on both thighs and legs, along with joint pain. He had a urinary tract infection for a week before the rash appeared. His skin showed several tender, ring-shaped, partially blanchable, red plaques on both sides of his thighs and legs. He was given oral prednisolone (40mg/day) for a week along with a non-drowsy antihistamine (fexofenadine). Within a week, all the rashes disappeared completely. There were no more rashes during the next 6 months of regular check-ups.
○ làimhseachadh ― OTC Drugs
Ma tha fiabhras ort (àrdachadh ann an teòthachd bodhaig), tha sinn a’ moladh gun iarr thu aire mheidigeach cho luath ‘s a ghabhas.
Bu chòir an droga a tha fo amharas a stad. (me antibiotics, drogaichean neo-steroidal anti-inflammatory)
Antihistamines beòil leithid cetirizine no loratadine airson tachas fhèin.
#Cetirizine [Zytec]
#LevoCetirizine [Xyzal]
#Loratadine [Claritin]
Is dòcha gum bi ointmentan steroid OTC neo-èifeachdach airson an comas ìosal. Feumar a chuir a-steach airson còrr air seachdain gus adhartas fhaicinn.
#Hydrocortisone ointment